

Resource Summary Report

Generated by [RRID](#) on Sep 8, 2026

CD8a Monoclonal Antibody (4SM16), eBioscience

RRID:AB_2637159

Type: Antibody

Proper Citation

Thermo Fisher Scientific Cat# 14-0195-82, RRID:AB_2637159

Antibody Information

URL: http://antibodyregistry.org/AB_2637159

Proper Citation: Thermo Fisher Scientific Cat# 14-0195-82, RRID:AB_2637159

Target Antigen: CD8a

Host Organism: rat

Clonality: monoclonal

Comments: Applications: IHC-F, IHC-P

Antibody Name: CD8a Monoclonal Antibody (4SM16), eBioscience

Description: This monoclonal targets CD8a

Target Organism: mouse

Clone ID: Clone 4SM16

Antibody ID: AB_2637159

Vendor: Thermo Fisher Scientific

Catalog Number: 14-0195-82

Record Creation Time: 20251216T073902+0000

Record Last Update: 20260903T220045+0000

Ratings and Alerts

No rating or validation information has been found for CD8a Monoclonal Antibody (4SM16), eBioscience.

No alerts have been found for CD8a Monoclonal Antibody (4SM16), eBioscience.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Szabova L, et al. (2026) High-grade serous ovarian cancer induced in different sites of origin in mice exemplifies diverse features of the human disease. *iScience*, 29(1), 114238.

Xu Z, et al. (2026) Unbiased niche labeling maps immune-excluded niche in bone metastasis. *Cell*, 189(11), 3287.

Benmeharek MR, et al. (2025) Anti-vascular endothelial growth factor treatment potentiates immune checkpoint blockade through a BAFF- and IL-12-dependent reprogramming of the TME. *Immunity*, 58(4), 926.

Kastner AL, et al. (2025) Durable lymphocyte subset elimination upon a single dose of AAV-delivered depletion antibody dissects immune control of chronic viral infection. *Immunity*, 58(2), 481.

Yu L, et al. (2025) Tumor-derived arachidonic acid reprograms neutrophils to promote immune suppression and therapy resistance in triple-negative breast cancer. *Immunity*, 58(4), 909.

Nie H, et al. (2025) Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer. *Cancer research*, 85(18), 3471.

Shammas G, et al. (2025) Neurons undergo IFN γ -driven persistent epigenetic shifts and synaptopathy in encephalitis. *Neuron*.

Meza-Perez S, et al. (2024) Proteobacteria impair anti-tumor immunity in the omentum by consuming arginine. *Cell host & microbe*, 32(7), 1177.

Schratz KE, et al. (2023) T cell immune deficiency rather than chromosome instability predisposes patients with short telomere syndromes to squamous cancers. *Cancer cell*, 41(4), 807.

Qadir AS, et al. (2021) CD95/Fas protects triple negative breast cancer from anti-tumor activity of NK cells. *iScience*, 24(11), 103348.

Kaczanowska S, et al. (2021) Genetically engineered myeloid cells rebalance the core immune suppression program in metastasis. *Cell*, 184(8), 2033.

El Meskini R, et al. (2021) Distinct Biomarker Profiles and TCR Sequence Diversity Characterize the Response to PD-L1 Blockade in a Mouse Melanoma Model. *Molecular*

cancer research : MCR, 19(8), 1422.

Daglas M, et al. (2019) Activated CD8+ T Cells Cause Long-Term Neurological Impairment after Traumatic Brain Injury in Mice. Cell reports, 29(5), 1178.